Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 – 2024
Int. Journal of Clinical Pharmacology and Therapeutics · 01.10.2026 · 64 (10) · 514-525
DOI: 10.5414/cp204980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.10.2026. Verfasst von Lidan Tu und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Human Growth Hormone, Adverse Drug Reaction Reporting Systems, Growth Disorders.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Tu, L., Jiang, H., Liu, J., Lin, Y., Wang, S., Tu, Y., & Hong, Q. (2026). Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 – 2024. Int. Journal of Clinical Pharmacology and Therapeutics, 64(10), 514-525. https://doi.org/10.5414/cp204980
Vancouver
Tu L, Jiang H, Liu J, Lin Y, Wang S, Tu Y, et al. Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 – 2024. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(10):514-525. doi:10.5414/cp204980
BibTeX
@article{Tu2026,
author = {Tu, Lidan and Jiang, Huafeng and Liu, Jianming and Lin, Yimin and Wang, Shuping and Tu, Ying and Hong, Qingxia},
title = {Recombinant human growth hormone in pediatric patients using the FAERS database: Safety profile and update for the period 2004 – 2024},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {10},
pages = {514--525},
doi = {10.5414/cp204980}
}
EUVIMED